Characterization of tau positron emission tomography tracer [18F]AV-1451 binding to postmortem tissue in Alzheimer's disease, primary tauopathies, and other dementias
Characterization of tau positron emission tomography tracer [18F]AV-1451 binding to postmortem tissue in Alzheimer's disease, primary tauopathies, and other dementias
复制标题
DOI：
10.1016/j.jalz.2016.01.003
复制
发表时间：
2016-11-01
影响因子：
14
通讯作者：
Arstad, Erik
中科院分区：
文献类型：
--
作者：
Sander, Kerstin;Lashley, Tammaryn;Arstad, Erik
简介：tau蛋白聚集是许多神经退行性疾病的标志，利用正电子发射断层扫描（PET）进行tau蛋白成像可能有助于早期诊断和治疗监测。我们评估了PET示踪剂[F-18]AV-1451在一系列痴呆症中的结合。方法：采用磷成像技术定量结合33例不同组织病理学特征的神经退行性痴呆患者的死后脑组织。结果：[F-18]AV-1451在阿尔茨海默病（AD）中表现出高特异性结合，在匹克病和额颞叶痴呆伴帕金森-17中表现出中等程度的结合，在皮质基底变性、进行性核上性麻痹、非tau蛋白病变和无病理对照中表现出低但可置换的结合。示踪剂结合与疾病组内的tau负荷无关。讨论：[F-18]AV-1451在AD和其他一些tau病变中与tau结合。然而，非tau结合位点的证据和示踪剂结合与抗体染色之间缺乏相关性表明，用这种示踪剂可靠地定量tau负荷是有问题的。(C) 2016年阿尔茨海默病协会。Elsevier Inc.出版。版权所有。
Introduction: Aggregation of tau is a hallmark of many neurodegenerative diseases, and tau imaging with positron emission tomography (PET) may allow early diagnosis and treatment monitoring. We assessed binding of the PET tracer [F-18]AV-1451 in a range of dementias.Methods: Phosphorimaging was used to quantify binding to postmortem brain tissue from 33 patients with different, histopathologically characterized, neurodegenerative dementias.Results: [F-18]AV-1451 showed high specific binding in cases with Alzheimer's disease (AD), moderate binding in Pick's disease and frontotemporal dementia with parkinsonism-17, and low but displaceable binding in corticobasal degeneration, progressive supranuclear palsy, non-tau proteino-pathies, and in controls without pathology. Tracer binding did not correlate with tau load within disease groups.Discussion: [F-18]AV-1451 binds to tau in AD, and some other tauopathies. However, evidence for a non tau binding site and lack of correlation between tracer binding and antibody staining suggest that reliable quantification of tau load with this tracer is problematic. (C) 2016 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.